TFRC and COVID-19: A lower concentration of 5-sialoTRF in patients with an accompanying chronic disease should therefore be treated as an additional burdening factor for patients with COVID-19, as these isoforms have a lower affinity for transferrin receptors, which intensifies respiratory disorders in these patients [11,12].